NCT07023094 PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
| NCT ID | NCT07023094 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Poznan University of Medical Sciences |
| Condition | Hip Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2025-06-16 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.
Eligibility Criteria
Inclusion Criteria: * Pediatric patients aged between 2 and 16 years. * Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries * ASA (American Society of Anesthesiologists) physical status classification: I-III. * Written informed consent obtained from the patient's legal guardian(s). Exclusion Criteria: * Known allergy or hypersensitivity to any of the study medications * Presence of infection or inflammation at the intended injection site(s) of regional anesthesia. * Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks. * Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs. * Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation. * History of chronic opioid use or known substance abuse. * Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.
Contact & Investigator
Malgorzata Reysner, M.D. Ph.D.
PRINCIPAL INVESTIGATOR
Poznan University of Medical Sciences
Frequently Asked Questions
Who can join the NCT07023094 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 16 Years, studying Hip Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07023094 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07023094 currently recruiting?
Yes, NCT07023094 is actively recruiting participants. Contact the research team at mreysner@ump.edu.pl for enrollment information.
Where is the NCT07023094 trial being conducted?
This trial is being conducted at Poznan, Poland.
Who is sponsoring the NCT07023094 clinical trial?
NCT07023094 is sponsored by Poznan University of Medical Sciences. The principal investigator is Malgorzata Reysner, M.D. Ph.D. at Poznan University of Medical Sciences. The trial plans to enroll 60 participants.